Cantor Fitzgerald initiated coverage of United Therapeutics (UTHR) with an Overweight rating and $405 price target
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on UTHR:
- Maintaining Market Position: United Therapeutics’ Tyvaso DPI Amidst Competition and Future Growth Prospects
- Liquidia price target raised to $23 from $20 at Wells Fargo
- Hold Rating for United Therapeutics Amid Competitive Pressures from LQDA’s Yutrepia
- Liquidia price target raised to $37 from $29 at BTIG
- Liquidia price target raised to $31 from $27 at Jefferies